Bandaríkin - enska - NLM (National Library of Medicine)

gm holdings co., ltd - ceramide 3 (unii: 4370df050b) (ceramide 3 - unii:4370df050b) - ceramide 3 0.05 in 200 ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - borax 12%; glycerol 88% - oral solution - 12 % - active: borax 12% glycerol 88%

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 10.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 15.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 50.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - anidulafungin, quantity: 100 mg - injection, powder for - excipient ingredients: tartaric acid; mannitol; fructose; polysorbate 80 - treatment of invasive candidiasis, including candidaemia in adult and in paediatric patients one month and older (see section 5.1)

Ísrael - enska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - anidulafungin - powder for concentrate for solution for infusion - anidulafungin 100 mg/vial - anidulafungin - anidulafungin - treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years

Úganda - enska - National Drug Authority

sev pharmaceuticals limited; sev pharmaceuticals limited - glycerine+borax - oral liquid ordinary liquids - 12%w/v

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) - powder for injection - 200 u - active: taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) excipient: citric acid mannitol polysorbate 80 sodium citrate dihydrate - elelyso is indicated for long-term enzyme replacement therapy for adult and paediatric patients with a confirmed diagnosis of type 1 gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anaemia, thrombocytopenia.

Evrópusambandið - enska - EMA (European Medicines Agency)

zoetis belgium sa - toceranib - antineoplastic agents - dogs - treatment of non-resectable patnaik grade-ii (intermediate-grade) or -iii (high-grade), recurrent, cutaneous mast-cell tumours in dogs.